Clinical Trial Update: Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation [Phase 1]

View source ↗

Summary

The update covers an ongoing Phase 1 basket trial evaluating Neratinib plus Everolimus, Palbociclib, or Trametinib in patients with refractory and advanced or m…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Solid Tumor

Drugs mentioned

• Everolimus (everolimus)
• Palbociclib (palbociclib)
• Trametinib (trametinib)
• neratinib (neratinib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Advanced Malignant Solid Neoplasm, EGFR Gene Amplification | Phase 1 | Status: ACTIVE_NOT_RECRUITING